文献速递前列腺增生与排尿功能障碍

良性前列腺增生手术治疗方案的成本效益评估

Evaluation of the Cost-Effectiveness of Surgical Treatment Options for Benign Prostatic Hyperplasia.
PubMed 文献 · Urology · 2022-10-19

本研究采用马尔可夫模型进行成本-效用分析,比较前列腺体积<80cc时HoLEP、B-TURP、WVTT与PUL,以及>80cc时HoLEP与SP的成本效益。5年时HoLEP在前列腺体积<80cc患者中QALYs最高(4.66)且最具成本效益(ICER 11847美元/QALY),在前列腺体积>80cc患者中较SP成本更低且效果更优。结论认为5年随访下HoLEP是良性前列腺增生具有成本效益的手术治疗,与腺体大小无关。

要点

  • 前列腺体积<80cc患者5年时HoLEP的QALYs最高(4.66),ICER为11847美元/QALY。
  • 前列腺体积>80cc患者中HoLEP较SP成本更低(6585美元 vs 15404美元)且更有效(4.654 vs 4.650 QALYs)。
  • 敏感性分析显示HoLEP成本翻倍或术后慢性压力性尿失禁增加十倍时B-TURP最具成本效益。

核心结论

  • 5年随访下HoLEP是良性前列腺增生具有成本效益的手术治疗,与腺体大小无关。

研究设计与样本

  • 采用马尔可夫模型进行成本-效用分析,比较前列腺体积<80cc(索引患者1)的HoLEP、B-TURP、WVTT和PUL,以及前列腺体积>80cc(索引患者2)的HoLEP和SP。
  • 模型概率和效用值取自文献,分析时间范围为5年并外推至终生,支付意愿阈值为100000美元/QALY。

主要发现

  • 5年时索引患者1每例成本:WVTT 3292美元、HoLEP 6532美元、B-TURP 6670美元、PUL 10257美元。
  • 索引患者1的QALYs:HoLEP最高(4.66),其次B-TURP(4.60)、PUL(4.38)、WVTT(4.38),HoLEP最具成本效益(ICER 11847美元/QALY)。
  • 索引患者2中HoLEP较SP成本更低(6585美元 vs 15404美元)且更有效(4.654 vs 4.650 QALYs)。
  • 敏感性分析中,若HoLEP成本增加两倍或HoLEP术后慢性压力性尿失禁增加十倍,B-TURP变为最具成本效益。
  • 随访时间变化时,极短随访(<1年)下WVTT更优,随访越长HoLEP优势越明显。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To compare the cost-effectiveness of surgical interventions for BPH. METHODS: Using a Markov model, a cost-utility analysis was performed comparing HoLEP, B-TURP, WVTT, and PUL for prostate size <80cc (index patient 1) and HoLEP and SP for prostate size >80cc (index patient 2). Model probabilities and utility values were drawn from the literature. Analysis was performed at a 5-year time horizon with extrapolation to a lifetime horizon. Primary outcomes included quality-adjusted life years (QALYs), 2021 Medicare costs, and incremental cost-effectiveness ratios (ICERs) with a willingness-to-pay threshold of $100,000/QALY. Univariate and probabilistic sensitivity analyses were performed. RESULTS: At 5 years, costs per patient for index patient 1 were $3292 (WVTT), $6532 (HoLEP), $6670 (B-TURP), and $10,257 (PUL). HoLEP resulted in the highest QALYs (4.66), followed by B-TURP (4.60), PUL (4.38), and WVTT (4.38). This translated to HoLEP being most cost-effective (ICER $11,847). For index patient 2, HoLEP was less costly ($6,585 vs $15,404) and more effective (4.654 vs 4.650) relative to SP. On sensitivity analysis for index patient 1, B-TURP became most cost-effective if cost of HoLEP increased two-fold or chronic stress incontinence following HoLEP increased ten-fold. When follow-up time was varied, WVTT was preferred at very short follow up (<1 year), and HoLEP became more strongly preferred with longer follow up. CONCLUSION: At 5 years follow up, HoLEP is a cost-effective surgical treatment for BPH- independent of gland size.

来源:Urology,查看原文。版权归原作者所有。

引用

  1. Wymer KM, Narang G, Slade A, et al. Evaluation of the Cost-Effectiveness of Surgical Treatment Options for Benign Prostatic Hyperplasia. Urology. 2022. PMID: 36270339. doi:10.1016/j.urology.2022.09.026

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。